Trial ID: | L0022 |
Source ID: | NCT06752577
|
Associated Drug: |
Allogeneic, Vertebral Bone Marrow-Derived Mesenchymal Stem Cells (Msc)
|
Title: |
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients with Chronic Kidney Disease (CKD)
|
Acronym: |
|
Status: |
RECRUITING
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Chronic Kidney Diseases
|
Interventions: |
DRUG: Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
|
Outcome Measures: |
Primary: Adverse events and/or serious adverse events, Number of adverse events and/or serious adverse events associated with mesenchymal stem cells intervention, 6 months |
|
Sponsor/Collaborators: |
Sponsor: Mayo Clinic | Collaborators: Ossium Health, Inc.
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
|
Enrollment: |
50
|
Study Type: |
OBSERVATIONAL
|
Study Designs: |
Observational Model: |Time Perspective: p
|
Start Date: |
2024-12-22
|
Completion Date: |
2031-12-31
|
Results First Posted: |
|
Last Update Posted: |
2024-12-30
|
Locations: |
Mayo Clinic, Jacksonville, Florida, 32224, United States
|
URL: |
https://clinicaltrials.gov/show/NCT06752577
|